玻璃体腔注射雷珠单抗治疗老年性黄斑变性的临床分析

Clinical Analysis of Intravitreal Injection of Ranibizumab in Treatment of Senile Macular Degeneration

目的分析玻璃体腔注射雷珠单抗治疗老年性黄斑变性临床效果。方法将42例老年性黄斑变性患者分为治疗组(玻璃体腔注射雷珠单抗)和对照组(视网膜光凝),各21例,比较两组患者临床治疗效果。结果治疗组患者治疗后最佳矫正视力、眼压和CMT均同对照组患者之间具有一定差异性,且同治疗前差异显著;两组患者治疗后FFA黄斑区无明显荧光渗漏率分别为52.38%、28.57%,差异有统计学意义(P<0.05);两组患者并发症发生率分别为14.29%、14.29%,差异无统计学意义(P>0.05)。结论玻璃体腔注射雷珠单抗治疗老年性黄斑变性效果显著。

Objective To analyzed the Clinical effect of intravitreal injection of ranibizumab in treatment of senile macular degeneration. Methods 42 patients with age-related macular degeneration were divided into treatment group（intravitreal injection of ranibizumab） and control group（retinal photocoagulation） with 21 cases in each group. Clinical curative effect was compared between the two groups. Results Best corrected visual acuity, intraocular pressure and CMT in the treatment group after treatment were similar to those in control group,and the difference between those of the two groups after treatment was statistically significant than those of the two groups before treatment（P〈0.05）;Obvious fluorescent FFA macular leakage were not found after treatment in 52.38% of the patients of the treatment group and 28.57% of patients of the control group, and the difference was statisti-cally significant（P〈0.05）; Complication rates of the two groups were 14.29%, 14.29%,respectively,and the difference was not statistically significant（P〉0.05）. Conclusion Intravitreal injection of ranibizumab has remarkable effect for the treatment of age-related macular degeneration.